Intellia reports CRISPR therapy outperforms traditional drugs in cardiomyopathy study

Intellia Therapeutics presented new data at the American Heart Association meeting, showing its CRISPR gene-editing treatment for ATTR cardiomyopathy outperformed traditional drugs from Alnylam and others. This update comes after previous positive trial results did not boost the company's stock, raising questions about the effectiveness of its CRISPR therapies compared to older treatments. The latest findings are based on a year-long study involving 36 patients, aiming to address concerns about the advantages of Intellia's CRISPR-based approach.